文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

短效致幻剂干预重度抑郁症:IIa期随机安慰剂对照试验

A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.
PubMed 文献 · Nat Med · 2026-02-16

该IIa期双盲随机安慰剂对照试验评估了单次静脉注射21.5毫克二甲基色胺(DMT)在34名中重度抑郁症成人中的疗效与安全性。2周时DMT组蒙哥马利-奥斯伯格抑郁评定量表(MADRS)评分下降显著优于安慰剂组(均差-7.35,95%CI -13.62至-1.08,P=0.023)。开放标签阶段抗抑郁效应持续至3个月,不良事件多为轻中度,无严重不良事件。

要点

  • 单次21.5毫克DMT静脉输注联合心理治疗支持在2周时MADRS评分改善显著优于安慰剂。
  • 开放标签阶段抗抑郁效应持续至3个月,接受一剂与两剂DMT者间无显著差异。
  • 不良事件多为轻中度,常见输注部位疼痛、恶心和短暂焦虑,无严重不良事件。

核心结论

  • 单次DMT联合心理治疗支持可快速、显著减轻抑郁症状,并持续至3个月,治疗耐受性良好且安全。

研究设计与样本

  • IIa期双盲随机安慰剂对照临床试验,纳入中重度抑郁症成人,共34例随机分组,17例接受安慰剂后活性药物,17例接受活性药物后活性药物。
  • 参与者接受单次21.5毫克DMT或安慰剂10分钟静脉输注,并辅以支持性心理治疗,随后进行2周评估,之后开放标签阶段所有参与者接受第二次DMT给药。

主要发现

  • 2周时DMT组MADRS评分下降显著大于安慰剂组(均差-7.35;95%CI -13.62至-1.08;P=0.023)。
  • 开放标签阶段抗抑郁效应持续至3个月,接受一剂与两剂DMT者间无显著差异。
  • 不良事件多为轻中度,常见输注部位疼痛、恶心和短暂焦虑,无严重不良事件发生。

关键数值与推荐

  • 主要结局为2周时MADRS评分变化;次要结局包括应答(MADRS评分降低≥50%)和缓解(MADRS≤10)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Major depressive disorder (MDD) is a leading cause of disability worldwide, yet many patients have inadequate responses to current treatments. Dimethyltryptamine (DMT), a serotonergic psychedelic with rapid onset and short duration, shows promise as a potential antidepressant (AD), although clinical evidence in MDD remains limited. We conducted a phase IIa, double-blind, placebo-controlled, randomized clinical trial to evaluate the efficacy and safety of intravenous DMT (SPL026; DMT fumarate) in adults with moderate-to-severe MDD. Participants received a single 21.5-mg dose of DMT or placebo infused over 10 min, along with supportive psychotherapeutic support, followed by a 2-week assessment. A subsequent open-label phase offered all participants a second DMT dose. The primary outcome was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) at 2 weeks. Secondary outcomes included response (≥50% reduction in MADRS score) and remission (MADRS ≤ 10). A total of 34 participants were randomized, 17 to placebo-active and 17 to active-active. At 2 weeks, the DMT group showed a significantly greater reduction in MADRS score than placebo (mean difference = -7.35; 95% CI = -13.62 to -1.08; P = 0.023). In the open-label phase, AD effects persisted up to 3 months, with no significant differences between those who received one versus two doses. Adverse events were mostly mild to moderate, commonly infusion site pain, nausea and transient anxiety. No serious adverse events occurred. A single dose of DMT with psychotherapeutic support produced a rapid, significant reduction in depressive symptoms, sustained up to 3 months. The treatment was well-tolerated and safe. ClinicalTrials.gov registration: NCT04673383 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Erritzoe D, Barba T, Benway T, et al. A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial. Nat Med. 2026. PMID: 41699126. doi:10.1038/s41591-025-04154-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。